Business
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism – – SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – – Cash balance of approximately $73.0 million as of December 31, 202
About this update from Shattuck Labs, Inc.
[{"type":"image","alt":"Shattuck Labs, Inc.","displaySize":"","headline":null,"caption":"Shattuck Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_.4r1lpCFq8StfajNT2qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8","width":300,"height":69}},"lazy":false},{"type":"text","content":"– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –","length":342,"tagName":"p"},{"type":"text","content":"– SL-325 advances toward Phase 1; on track for IND filing in the third quarter of 2025 – ","length":88,"tagName":"p"},{"type":"text","content":"– Cash balance of approximately $73.0 million as of December 31, 2024, expected to fund operations into 2027 –","length":110,"tagName":"p"},{"type":"text","content":"AUSTIN, TX and DURHAM, NC, March 27, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business highlights.","length":454,"tagName":"p"},{"type":"text","content":"“Shattuck made the difficult but appropriate decision to terminate our SL-172154 program in 2024, and rapidly transitioned to our potential first-in-class DR3 blocking antibody, SL-325,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “In February, we presented preclinical results from our IND-enabling GLP toxicology study for SL-325 at ECCO, demonstrating differentiation from TL1A blocking monoclonal antibodies, along with a favorable safety profile, full receptor occupancy, and lack of DR3 agonism. Our encouraging preclinical data underscore SL-325’s potential for DR3 blockade to provide po...